NodThera is developing NLRP3 inflammasome inhibitors to target chronic inflammatory diseases at their source, including obesity, cardiometabolic, and neurodegenerative conditions. By focusing on this upstream catalyst of inflammation, NodThera aims to provide effective treatments that improve patient outcomes and quality of life.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Chronic inflammatory diseases, including obesity, cardiometabolic disorders, and neurodegenerative conditions, are driven by the NLRP3 inflammasome, an upstream catalyst of inflammation. Current treatments often fail to address the root cause of inflammation, leading to suboptimal patient outcomes and reduced quality of life.
Solution
NodThera is developing a portfolio of NLRP3 inflammasome inhibitors designed to target chronic inflammatory diseases at their source. By inhibiting the NLRP3 inflammasome, NodThera aims to interrupt the inflammatory cascade and provide effective treatments for a range of conditions. Their approach is based on scientific evidence supporting the NLRP3 inflammasome as a key driver of inflammation in diseases affecting both the body and the brain. NodThera's molecules and data are intended to establish a new standard in the NLRP3 inflammasome space, offering the potential to improve the lives of patients suffering from obesity, cardiometabolic, and neurodegenerative diseases.
Target Audience
The primary target audience includes patients suffering from chronic inflammatory diseases such as obesity, cardiometabolic disorders, and neurodegenerative conditions, as well as healthcare providers seeking more effective treatment options.
Features
- Focus on developing inhibitors specifically targeting the NLRP3 inflammasome.
- Aims to address the upstream catalyst of inflammation, offering a potentially more effective treatment approach.
- Portfolio of molecules with pre-clinical and clinical data.
- Potential applications in obesity, cardiometabolic disorders, neuroinflammation, cardiovascular disease and osteoarthritis.